AlgaeNet4AV Training network for exploring microalgae diversity for the development of novel antiviral compounds
- Coordinator
- Ethniko Kentro Erevnas Kai Technologikis Anaptyxis, Greece
- Runs
- 1 January 2023 to 31 December 2026
- Status
- Running
- EU funding
- €773k
- Total cost
- —
- Partners
- 14 organisations in 10 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101086437
What the project is doing
In the project's own words, from its summary on CORDIS.
The AlgaeNet4AV project seeks to exploit the microalgae biodiversity, as a source for high-added-value lectins and polyphenols with antiviral properties against influenza and coronavirus pandemic strains. Microalgae derived-compounds are easily amendable, bio-degradable, non-toxic and safe; thus, they are preferred to be used for the development of novel bio-based materials and cosmetics with antiviral potential. Lectins and polyphenols could be highly demanded non-drug interventions across the materials and cosmetics industry as a solution to reduce the risk and speed of contamination and transmission during pandemic outbreaks.
The project will combine the whole value chain in order to: a) develop transcriptomics and metabolomics resources from microalgae diversity as a valuable source for the discovery novel lectins and polyphenols; b) characterize their spectrum of bioactivity and toxicity and provide structure-function relationships; c) develop and optimize application-based microalgae culture systems and downstream processing strategies for higher production rate of the desired compounds; d) develop, formulate and evaluate lectins and polyphenols-based final cosmetics products.
The work will be supported by market assessment, integral biorefinery designs, techno-economic and sustainability assessment. Integrated value chains will be demonstrated to deliver proof-of-concept and demonstrate economic feasibility. AlgaeNet4AV is an industry-academia R&D and innovation project with a multidisciplinary approach aimed at generating robust business cases through technology development. The consortium composed by 11 partners, with 7 European and 2 third-country (USA & Japan) prominent research organisations.
Strong industrial leadership is guaranteed through the participation of 5 SMEs. The projects goals will be achieved through a sustainable way helping meet the increasing demand while creating a positive environmental impact through reduction of carbon emissions.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Ethniko Kentro Erevnas Kai Technologikis Anaptyxis | Thermi Thessaloniki | Greece | Coordinator |
| Zurcher Hochschule Fur Angewandte Wissenschaften | Winterthur | Switzerland | Associatedpartner |
| Technologiko Panepistimio Kyprou | Lemesos | Cyprus | Participant |
| Danmarks Tekniske Universitet | Kongens Lyngby | Denmark | Participant |
| Enzyceuticals Idiotiki Kefalaiouchiki Etaireia | Athens | Greece | Participant |
| Fresh Formula Private Limited Cosmetics Manufacturing Company | Koropi | Greece | Participant |
| Geoponiko Panepistimion Athinon | Athina | Greece | Participant |
| Lab Analysis Life Science SL | Valencia | Spain | Participant |
| Particula Group Drustvo S Ogranicenom Odgovornoscu Za Istrazivanje Razvoj I Proizvodnju | Viskovo | Croatia | Participant |
| Fondazione Edmund Mach | San Michele All Adige | Italy | Participant |
| National University Corporation Tohoku University | Sendai | Japan | Associatedpartner |
| Allmicroalgae Natural Products SA | Pataias | Portugal | Participant |
| Necton-Companhia Portuguesa De Culturas Marinhas SA | Fuseta | Portugal | Participant |
| The Regents of the University of California | Oakland | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI